These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

947 related articles for article (PubMed ID: 21199268)

  • 1. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.
    Arechavaleta R; Seck T; Chen Y; Krobot KJ; O'Neill EA; Duran L; Kaufman KD; Williams-Herman D; Goldstein BJ
    Diabetes Obes Metab; 2011 Feb; 13(2):160-8. PubMed ID: 21199268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin.
    Violante R; Oliveira JH; Yoon KH; Reed VA; Yu MB; Bachmann OP; Lüdemann J; Chan JY
    Diabet Med; 2012 Nov; 29(11):e417-24. PubMed ID: 22375612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes.
    Aschner P; Katzeff HL; Guo H; Sunga S; Williams-Herman D; Kaufman KD; Goldstein BJ;
    Diabetes Obes Metab; 2010 Mar; 12(3):252-61. PubMed ID: 20070351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.
    Nauck MA; Meininger G; Sheng D; Terranella L; Stein PP;
    Diabetes Obes Metab; 2007 Mar; 9(2):194-205. PubMed ID: 17300595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes.
    Williams-Herman D; Johnson J; Teng R; Golm G; Kaufman KD; Goldstein BJ; Amatruda JM
    Diabetes Obes Metab; 2010 May; 12(5):442-51. PubMed ID: 20415693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
    Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.
    Wainstein J; Katz L; Engel SS; Xu L; Golm GT; Hussain S; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 May; 14(5):409-18. PubMed ID: 22059736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
    Bergenstal RM; Wysham C; Macconell L; Malloy J; Walsh B; Yan P; Wilhelm K; Malone J; Porter LE;
    Lancet; 2010 Aug; 376(9739):431-9. PubMed ID: 20580422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
    Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
    Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial.
    Hartley P; Shentu Y; Betz-Schiff P; Golm GT; Sisk CM; Engel SS; Shankar RR
    Drugs Aging; 2015 Jun; 32(6):469-76. PubMed ID: 26041585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study.
    Seck T; Nauck M; Sheng D; Sunga S; Davies MJ; Stein PP; Kaufman KD; Amatruda JM;
    Int J Clin Pract; 2010 Apr; 64(5):562-76. PubMed ID: 20456211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
    Arai K; Maeda H; Sirabe S; Yamamoto R; Yamauchi M; Hirao T; Hirao S; Hirao K
    Diabetes Technol Ther; 2013 Apr; 15(4):335-41. PubMed ID: 23480592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
    Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.
    Srivastava S; Saxena GN; Keshwani P; Gupta R
    J Assoc Physicians India; 2012 Mar; 60():27-30. PubMed ID: 22799111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.